Daniella M. Schwartz completed her B.A. in Biochemistry and French at Rice University (cum laude) followed by an MD at the Wake Forest University School of Medicine (Alpha Omega Alpha). She completed a residency in Internal Medicine at Virginia Commonwealth University, where she also served as a chief medical resident. This was followed by a fellowship in clinical rheumatology at the National Institutes of Health, NIAMS, followed by postdoctoral training in the lab of Dr. John O’Shea. She also trained in translational immunology under the mentorship of Drs. Joshua Milner and Pamela Guerrerio and collaborated extensively with Dr. Daniel Kastner in the discovery and characterization of the immune dysregulatory disease haploinsufficiency of A20 (HA20). In 2022, Dr. Schwartz was recruited to the University of Pittsburgh, where she is currently an Assistant Professor in the Division of Rheumatology and Clinical Immunology. Her lab investigates the the intersection of allergy, autoimmunity, and autoinflammation, with a focus on T helper 9 cells, seronegative spondyloarthropathies. and genetic immune dysregulatory diseases. She helps oversee the University of Pittsburgh Immune Dysregulation Diagnosis and Treatment (IDDAT) Program and has an active protocol to study HA20 and related inborn errors of immunity. She has authored numerous peer-reviewed publications and was awarded the NPF Robertson Fellowship and ASCI Young Physician Scientist Award.